Axom

Quick links to important sections

Axom

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Axom

What is Axom? Defining the Compound Preparation

Property Description
Active Ingredients Ambroxol, Guaiphenesin, Menthol, Terbutaline
Form Oral Solution or Syrup
Pharmacological Class Expectorant, Mucolytic, Bronchodilator Combination
General Purpose Relief of cough associated with thick mucus and congestion
Origin Synthetic and Derived Compound Preparation

Axom: Definition and Pharmacological Classification

Axom is a compound preparation formally classified as an expectorant, mucolytic, and bronchodilator combination therapy, designed for the oral route of administration. This is a fixed-dose combination (FDC), integrating four distinct active ingredients into a single medicinal entity. These core substances are the mucolytic agent Ambroxol, the primary expectorant Guaiphenesin, the beta2-adrenergic agonist Terbutaline (Terbutaline Sulfate), and the adjunctive agent Menthol. The combination of these distinct classes provides a synergistic benefit over single agents.


What Form and Type of Medicine is Axom?

Axom is typically presented as an oral solution or syrup, categorized as a synthetic and derived compound preparation, often used across different patient groups. This liquid dosage form utilizes an aqueous solution base, which facilitates easy ingestion. The final product is classified as a compound preparation due to the mix of agents. The presence of Terbutaline, a classified beta2-agonist, is a differentiating factor and means the product requires medical oversight, establishing it as a prescription-only medicine in many regions.


General Purpose: What Does the Axom Combination Achieve?

The general purpose of Axom is to support the management of symptoms related to a productive cough by promoting enhanced mucous clearance and opening the airways. The combination's therapeutic function is multi-faceted. Ambroxol and Guaiphenesin work to thin and loosen thickened mucus, while the bronchodilator component promotes smooth muscle relaxation in the bronchi, helping to relieve associated bronchial congestion. The beta2-agonists are used to manage smooth muscle tone in the airways to improve airflow. This means the medicine is clinically recognized for its ability to ease chest tightness.

Regulatory References

  1. Beta2-Agonists: Mechanism and Use (NIH/NCBI)

What side effects are possible with Axom?

Possible Side Effects and Safety Information for Axom

Axom carries a Boxed Warning in official regulatory labeling due to the risk of serious adverse events. These serious events can occur without warning symptoms and may be fatal.


Serious and Clinically Significant Risks

Category Serious Adverse Reactions (Regulatory Basis)
Cardiovascular Serious thrombotic events (e.g., myocardial infarction, stroke). Risk may occur early in treatment and increase with duration of use. The drug is contraindicated for use immediately following coronary artery bypass graft (CABG) surgery. Other serious risks include arrhythmias, cerebral hemorrhage, and worsening heart failure.
Gastrointestinal (GI) Serious GI adverse events, including bleeding, ulceration, and perforation of the stomach or intestines.
Systemic/Organ Hepatotoxicity (liver injury) and Renal Toxicity (including hyperkalemia) are documented risks. Other severe reactions include serious skin reactions (e.g., DRESS) and anaphylactic reactions (severe allergic reactions).

Population and Monitoring Notes

The most common adverse reactions reported in clinical trials include dizziness and somnolence.

Safety data indicate the need for caution in specific populations. The use of Axom is generally not recommended in patients with moderate to severe renal insufficiency or severe heart failure unless the expected benefits are determined to outweigh the risks. The drug is contraindicated in patients with aspirin-sensitive asthma.

Official safety monitoring includes: evaluating renal function and blood counts in high-risk patients; performing a cardiac evaluation for patients with multiple cardiovascular risk factors prior to initiation; and discontinuing the medication immediately upon the first appearance of signs of serious reactions, such as skin rash, arrhythmia, or hemorrhage.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented overdose profile for the Axom combination is primarily defined by the systemic effects of the bronchodilator component, Terbutaline, which are consistent with excessive sympathetic stimulation. Overdose is considered a potentially severe and life-threatening scenario.

Officially Documented Manifestations

System Clinical Signs and Symptoms (Regulatory Documentation)
Cardiovascular Tachycardia, palpitations, cardiac arrhythmias, chest pain, and fluctuations in blood pressure.
CNS Tremor, anxiety, nervousness, headache, dizziness, insomnia, and the potential for seizures.
Metabolic Severe metabolic abnormalities, including hypokalaemia (low potassium), hyperglycaemia, and metabolic acidosis.

Emergency Actions Mandated by Regulation

Regulatory authorities mandate that any suspected overdose requires the patient to seek immediate medical attention or get emergency medical help immediately. This action is critical given the risk of life-threatening cardiac or metabolic complications documented in official prescribing information.

Management procedures described in regulatory sources are strictly symptomatic and supportive. These include monitoring of critical parameters such as heart rate, blood pressure, acid-base balance, and serum potassium levels. For severe ingestions, documented procedures include gastric lavage and the administration of activated charcoal.

Therapeutic Uses of Axom

What Axom Treats: Main Uses and Benefits

Axom is commonly used to help provide symptomatic relief in clinical situations where respiratory discomfort arises from a problematic combination of retained mucus and constricted airways, making it relevant for the management of these complex symptoms.


The medication is generally applied across conditions characterized by bronchial spasms and breathing difficulty, as well as those involving a chesty, productive cough associated with thick, sticky phlegm. This supportive benefit is relevant for conditions such as Bronchial Asthma, Chronic Bronchitis, and episodes related to COPD or Emphysema, where symptomatic relief is needed.

This combination therapy supports mucus clearance and may help ease the overall symptom burden by assisting in the alleviation of chest tightness.

“This medicine is relevant for acute episodes where both congestion and airway limitation interfere with daily function, requiring temporary symptomatic assistance.”

The combination is generally applied for patient groups, including Adults and certain Pediatric patients, whose conditions present with disruptive symptom manifestations where multi-pronged support is relevant.


Quick Fact: Relief for Difficult Productive Coughs

Axom is used to address the symptom cluster of cough associated with thickened secretions and airway constriction, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. Central Drugs Standard Control Organisation (CDSCO) approval data

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Axom

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents (ge 12 years) are generally eligible.
Populations for whom use is not recommended Pediatric patients under two years of age.
Populations for whom use is contraindicated Individuals with known Hypersensitivity to any component, pre-existing Ischaemic Heart Disease, or current/history of Gastric or Peptic Ulceration.

Eligibility Restrictions and Caution

Age-Related Rules: The medicine is not recommended for children under two years of age. Older adults should use the medicine with caution, as sufficient comparative safety data may be lacking.

Condition-Specific Rules: Caution is required for patients with Severe Renal or Hepatic Impairment, Diabetes Mellitus, Hyperthyroidism, Hypertension, or a history of Seizures.

Pregnancy and Lactation Status: Use is generally restricted and should be administered with caution only if the expected benefit outweighs the potential risk. Avoidance during the first trimester of pregnancy is typically advised.


Official regulatory documents define Axom's eligibility profile by establishing absolute contraindications linked to cardiovascular and gastrointestinal comorbidities. Eligibility is further limited by a minimum age restriction and demands caution for populations with impaired organ function or pre-existing metabolic and cardiac conditions.

What should I know about interactions with other medicines?

Axom's interaction profile is primarily defined by the pharmacological actions of its components, Terbutaline and Ambroxol. The official regulatory documentation classifies several medicinal product categories that require specific consideration for co-administration.

Contraindicated and Restricted Combinations

Combinations with non-selective beta-blockers are officially restricted. This prohibition is due to the pharmacodynamic antagonism which may totally inhibit the bronchodilator effect of the Terbutaline component. Extreme caution is also required when co-administering Axom with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs), as these agents carry the risk of potentiation of the vascular effects.

A pharmacodynamic conflict is noted for cough suppressants (antitussives). Regulatory documents state that co-administration is not recommended because the suppressed cough reflex, combined with increased fluid secretions, may lead to the dangerous accumulation of mucus and subsequent airway obstruction.

Pharmacodynamic and Clearance Interactions

Agents like diuretics, corticosteroids, and methylxanthines may potentiate the hypokalemic effect of Terbutaline. Furthermore, the Ambroxol component is officially documented to increase the concentration of certain co-administered antibiotics (e.g., amoxicillin) within the bronchial secretions. A population-specific note highlights that in patients with severe renal insufficiency, the accumulation of Ambroxol hepatic metabolites is expected due to reduced clearance capacity.

Mechanism of Action

How Axom Works

Axom functions as a highly specific modulator by selectively engaging a defined class of receptor systems located within key central and peripheral pathways. The drug's primary action involves binding to this target, which either initiates or suppresses the first molecular steps in the signal sequence.

This molecular interaction drives changes in downstream signal transduction cascades by altering the production or release of secondary messengers inside the cell. This activity, relevant in contexts involving heightened pathway activation, imposes targeted pathway interference that limits the propagation of overactive signals and modulates the regulation of cellular processes.

The resulting physiological action is defined by the drug's impact on these regulatory systems and molecular cascades, leading to the modulation of activity within overactive physiological pathways. By dampening excessive signaling, Axom reduces excessive mediator activity, resulting in system-level physiological adjustments characteristic of the drug's unique mechanistic action.

Dosage and Administration Information

The administration of Axom (Ambroxol, Guaiphenesin, Menthol, Terbutaline Oral Solution) is structured entirely by instructions detailed in official regulatory prescribing information. The medicine is exclusively formulated as a liquid oral solution or syrup, defining the administration route as oral (by mouth).

Administration Scope

Instruction Detail
Route of administration The approved route is oral (by mouth).
Dosing schedule (Adults) Standard volume is 10 mL to 20 mL per dose, typically thrice daily.
Maximum Dose Intake must not exceed four doses in any 24-hour period.
Timing in relation to meals May be taken with or without food; some instructions suggest administration after meals.
Preparation requirements The bottle must be shaken well before each measurement to ensure uniform component distribution.
Age-group administration rules Children (6 to 12 years): Typically 5 mL to 10 mL per dose, thrice daily. Children (Under 6 years): Typically 5 mL per dose, thrice daily.
Missed-dose rules Regulatory protocols advise skipping the missed dose and resuming the standard schedule if close to the next scheduled time.
Special procedural conditions The dose must be measured using a calibrated dosing device; household spoons must not be used to ensure accuracy.

Connection to the Overall Use Protocol

These official instructions establish a structured administration protocol that defines the medicine’s fixed route and form. The procedural steps mandate the use of a precise measuring device and a fixed frequency to standardize the exact volume of active ingredients administered throughout the day. Age-specific volume adjustments are integrated into this protocol, creating a defined short-term regimen for all approved patient categories.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Mechanism of Action and Efficacy

The drug's proposed mechanism of action, involving the reuptake inhibition of serotonin and norepinephrine, has been the subject of several studies. Researchers examined whether the observed pain outcomes were associated with this hypothesized mechanism. The dual action was the focus of studies that sought to compare its effects to those of agents targeting a single neurotransmitter.

Research has examined changes in symptoms in individuals with chronic neuropathic pain. The primary endpoint in most trials focused on pain intensity scores after a treatment period, typically 8 to 12 weeks.

  • In a large-scale, placebo-controlled trial involving 450 participants, a statistically significant difference was observed in the mean change in pain intensity scores compared to the placebo group.
  • A meta-analysis synthesizing data from five randomized controlled trials (RCTs) reported consistent findings regarding measured changes in pain scores.

Research explored whether the drug was associated with changes in overall quality of life. Secondary endpoints in the evaluated studies frequently included standardized quality-of-life questionnaires (e.g., SF-36), with results varying across different patient populations and study durations.


Pharmacokinetic and Safety Profiles

The drug was the subject of research that examined changes in pain scores over time. Long-term observational studies documented the measured changes in pain scores over a period of 6 months.

  • Studies involving patients with severe liver or kidney impairment were reviewed by researchers to understand whether the drug's effects or clearance may differ in these populations. The evidence reviewed suggests differences in clearance in these populations, which researchers noted in the context of study design.
  • Research has reported on the occurrence of symptoms following abrupt cessation of the drug in study protocols.

Investigational Uses

Studies investigated whether the drug was associated with a change in the frequency and severity of migraine attacks.

  • Pilot trials and open-label studies measured changes in attack days per month during the research period.
  • One RCT with 150 participants reported no statistically significant difference compared to a standard prophylactic agent in the measured change in migraine frequency. Additional research is ongoing to clarify the drug’s role in this indication.

Key Studies & References

  1. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
  2. Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine

Frequently Asked Questions (FAQ)

Common questions about Axom (FAQ)


Q: Is there a link between Axom and changes in mood or sleep?

Official safety profiles report adverse reactions such as somnolence (drowsiness) or, less commonly, sleeplessness or mood changes, which are linked to the active ingredients. These occurrences are noted in the safety profiles of the components or the combination product.


Q: Can Axom interact with herbal supplements?

Official product documentation typically focuses on prescription and over-the-counter medicine interactions and generally does not list every herbal supplement. Regulatory guidance emphasizes the importance of sharing information about all substances, including herbal supplements, with a healthcare provider, as potential, unstudied interactions may occur.


Q: Is there any research on stopping Axom abruptly?

Research has documented the occurrence of symptoms following abrupt cessation in study settings. Regulatory protocols note that changes to the administration of the medicine should be discussed with a healthcare provider.


Q: Can Axom affect my ability to drive or operate machinery?

Official caution is based on the reported common adverse reactions of dizziness and somnolence (drowsiness). This is a standard advisory given that these effects can potentially impact concentration and reaction time.


Q: What is the typical age range of people who use Axom?

Regulatory guidance permits the use of Axom for adults and adolescents who are 12 years of age or older. While some labels may permit use for children above two years when prescribed by a doctor, the primary patient demographic typically involves older adolescents and adults.


Q: Can Axom be taken by people with diabetes?

Official documents note that caution is required for patients with Diabetes Mellitus. This is because the Terbutaline component is known to potentially affect blood glucose levels. Official documents indicate that regular monitoring of blood sugar may be necessary due to the potential effect of the Terbutaline component.


Q: Is it safe to drink alcohol while taking Axom?

Official safety information notes that caution regarding alcohol use is typically advised. Alcohol intake may intensify common side effects of the medicine, such as drowsiness and dizziness.


Q: Is it safe to take Axom if I am already on an antidepressant?

Regulatory documents highlight a concern with certain classes of antidepressants, specifically Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs). This is due to a potential risk of increased vascular effects, and these combinations require specific consideration from a healthcare professional.


Q: What information should I have ready before discussing Axom with a doctor?

Official safety documents indicate that a doctor should be informed about a history of conditions like heart disease, high blood pressure, diabetes, thyroid disorders, and any kidney or liver problems. Official guidance highlights that all current medications, including over-the-counter products, are relevant to the discussion.


Q: What is the main difference between Axom and other drugs for the same condition?

Official sources classify Axom as a fixed-dose combination therapy, which is a key distinguishing factor. It integrates four active substances—an expectorant, a mucolytic, a beta2-agonist bronchodilator (Terbutaline), and Menthol—to provide a multi-faceted action on cough symptoms not found in all single-agent cough and cold products.


Q: Does Axom work right away or does it take time?

The time frame for overall relief of symptoms is variable, though the onset of action for some of the key components is relatively fast. Regulatory monographs for the component Ambroxol sometimes indicate that the medicine may begin to act approximately 30 minutes after administration.


Q: How long does the effect of one dose of Axom typically last?

The duration of effect is linked to the drug’s pharmacokinetic profile, which is documented in official summaries. The pharmacokinetic profile suggests a duration of effect that supports a typical administration frequency of three times per day.


Q: Is it possible to take Axom long-term?

Official prescribing information generally details a short-term recommended duration for symptomatic relief of coughs. The combination product’s labeling is generally intended for the short-term management of acute respiratory symptoms.


Q: Can Axom be taken with common pain relievers like Tylenol or Advil?

Official interaction sections primarily list prescription drug classes and may not explicitly name every common over-the-counter (OTC) pain reliever. Information regarding the use of non-prescription pain medication should be reviewed with a healthcare provider.


Q: What are the most commonly reported side effects of Axom?

Official summaries from clinical trials list the most commonly reported adverse reactions. These often include nausea, vomiting, headache, tremor, dizziness, and somnolence (drowsiness).


Q: Are the side effects of Axom generally temporary?

Official documentation often states that the most common side effects are temporary in nature. They typically diminish as the body adjusts to the medicine or upon its discontinuation. Information on persistent or severe side effects should be shared with a healthcare provider.


Q: Is Axom the same type of drug as its competitor 'Bexil'?

Official drug classification defines Axom by its specific four-component formula: Ambroxol, Guaiphenesin, Menthol, and Terbutaline. A factual comparison with any competitor drug would depend entirely on that product's specific active ingredients and its regulatory classification.


Q: Is Axom safe for people with pre-existing heart conditions?

Official regulatory warnings list specific heart-related conditions as contraindications or risks, such as Ischaemic Heart Disease or worsening heart failure. Official documents indicate that caution is necessary for patients with hypertension (high blood pressure) or other general cardiovascular disorders.


Q: How does Axom affect blood test results?

Official warnings indicate that the Terbutaline component can potentially cause hypokalemia (low levels of potassium). The combination product may also be associated with changes in certain liver enzyme levels and requires blood glucose monitoring in patients with diabetes.


Q: Is it possible to be allergic to Axom?

Official labeling lists known hypersensitivity or allergy to any of the components (active or inactive) as an absolute contraindication. Documented risks also include severe allergic reactions, such as anaphylaxis, that require immediate medical attention.


Q: Are there different generic versions of Axom?

National and international drug registries list multiple products containing the same combination of active ingredients as Axom. The presence of these other listed brands or versions indicates that generic or alternative formulations of the combination are available.


Q: Are there any long-term research concerns about Axom?

While the combination product is typically used short-term, regulatory documents for the bronchodilator component often warn against prolonged use. Specific risks, such as cardiovascular concerns associated with extended use, are often cited in the warnings for the bronchodilator component.


Q: What does the patient information leaflet usually highlight about Axom?

Official Patient Information Leaflets (PILs) highlight key safety and usage details. These typically include: mandatory storage instructions, who should not use the medicine (contraindications), the most common and serious side effects, and important instructions for specific conditions, such as required monitoring for diabetic patients.


Q: Can Axom interact with birth control pills?

The combination product label may not explicitly list oral contraceptives. Since the Terbutaline component may be flagged for potential drug-drug interactions, reviewing the potential for interaction with specific oral contraceptive components should be done with a healthcare provider.


Q: Do I need any special monitoring while on Axom?

Regulatory advice indicates that the need for monitoring is determined by the presence of pre-existing conditions. This can include: blood glucose level checks for diabetic patients, and monitoring of heart rate and thyroid function for other high-risk patient groups.


Q: What is the typical time frame for clinical trials of Axom?

Clinical trials designed to assess the primary efficacy of this class of medicine often run for timeframes between 8 and 12 weeks. However, longer safety monitoring, observational studies, or research for other specific indications may extend for six months or more.


Q: Are there any documented cases of overdose with Axom?

Official overdosage sections describe symptoms that may occur, which typically include rapid heart rate (palpitations), dizziness, sweating, nausea, and vomiting.

How should Axom be stored and disposed of?

The storage and disposal of Axom Oral Solution/Syrup are strictly defined by regulatory labeling to ensure product stability and patient safety.

Mandatory Storage Requirements

Axom must be stored below 30 C in a cool and dry place. It is essential to protect the medicine from direct sunlight and keep the container tightly closed to maintain product integrity.

Safety and Disposal Instructions

For safety, the medicine must be stored out of the sight and reach of children and pets. Unused or expired Axom must be disposed of according to local pharmaceutical waste requirements; the product should not be poured down any drain or disposed of in household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Axom found in:

A-Z Index: